愈肝散结颗粒对晚期肝癌患者血清VEGF及HIF-1α的影响
|
摘要
目的:探讨愈肝散结颗粒对晚期肝癌患者血清中血管内皮生长因子(vascular endothelialgrowth factor,VEGF)及缺氧诱导因子1α(hypoxia inducible factor 1α,HIF-1α)表达的影响。方法:将临床分期为Ⅲb～Ⅳ期的肝癌患者61例随机分为治疗组31例,对照组30例,治疗组口服愈肝散结颗粒;对照组口服安慰剂颗粒。另随机选择同时期20例正常体检患者为健康人群组,采用双抗体夹心ABC-ELLSA法定量检测治疗前后2组患者及健康人群组血清中VEGF及HIF-1α表达水平,并观察瘤体大小及临床症状改善情况。结果:治疗组及对照组患者血清VEGF及HIF-1α水平较健康人群呈上升趋势,但治疗组上升程度低于对照组(P<0.05);瘤体大小治疗组改善总有效率为6.5%,对照组为3.3%,2组比较差异无统计学意义(P>0.05);临床症状改善方面治疗组总有效率为87.1%,对照组为60.0%,2组比较差异有统计学意义(P<0.05)。结论:愈肝散结颗粒可能通过抑制VEGF/HIF-1α通路,减少肿瘤血管生成而减缓肿瘤生长。
Objective: To discuss the effects of Yu Gan SanJie granules on the expressions of serum VEGF and HIF-1α of the patients with advanced hepatoma. Methods: All 61 patients who were at the stages of Ⅲb～Ⅳ were randomized into 31 cases of the treatment group and 30 cases of the control group, the treatment group took YuGan SanJie granules orally while the control group accepted placebo granules. At the same time, 20 people who were undergoing health examination were randomly chosen as the group of healthy people, the expressions of serum VEGF and HIF-1α of the patients were detected before and after treating by double antibody sandwich ABC-Elisa method quantitatively, the improvements of clinical symptoms and the size of tumor body were observed. Results:The expressions of VEGF and HIF-1α of the patients in the treatment group and the control group were on the rise compared with healthy people, while the rise degree of the treatment group was lower than the degree of the control group(P<0.05); total effective rate of the tumor body improvements of the treatment group was 6.5%, higher than3.3% of the control group, while the difference had no statistical meaning(P>0.05); total effective rate of clinical symptoms of the treatment group was 87.1%, higher than 60.0% of the control group, and the difference had statistical meaning(P <0.05). Conclusion: YuGan SanJie granules could slow down the growth which might be realized by inhibiting VEGF/HIF-1α pathway and reducing tumor angionesis.
Objective: To discuss the effects of Yu Gan SanJie granules on the expressions of serum VEGF and HIF-1α of the patients with advanced hepatoma. Methods: All 61 patients who were at the stages of Ⅲb～Ⅳ were randomized into 31 cases of the treatment group and 30 cases of the control group, the treatment group took YuGan SanJie granules orally while the control group accepted placebo granules. At the same time, 20 people who were undergoing health examination were randomly chosen as the group of healthy people, the expressions of serum VEGF and HIF-1α of the patients were detected before and after treating by double antibody sandwich ABC-Elisa method quantitatively, the improvements of clinical symptoms and the size of tumor body were observed. Results:The expressions of VEGF and HIF-1α of the patients in the treatment group and the control group were on the rise compared with healthy people, while the rise degree of the treatment group was lower than the degree of the control group(P<0.05); total effective rate of the tumor body improvements of the treatment group was 6.5%, higher than3.3% of the control group, while the difference had no statistical meaning(P>0.05); total effective rate of clinical symptoms of the treatment group was 87.1%, higher than 60.0% of the control group, and the difference had statistical meaning(P <0.05). Conclusion: YuGan SanJie granules could slow down the growth which might be realized by inhibiting VEGF/HIF-1α pathway and reducing tumor angionesis.
引文
[1]李屏,韦巍,李明芬,等.原发性肝癌的中医及中西医结合临床治疗研究进展[J].河北中医,2018,40(4):628-632.
[2]Lai HC,Lin CC,Cheng KS,et al.Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess:a population-based cohort study[J].Gastroenterology,2014,146(1):129-137.
[3]孟亚平.索拉非尼联合TACE治疗进展期原发性肝癌的临床研究[J].肝脏,2016,21(10):867-870.
[4]Guo Rp,Zhong C,Shim,et al.Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocelluar carcinoma[J].cancer Res clin oncol,2006,132(9):547-555.
[5]Zhao X,Ning Q,Sun X,et al.Pokemon reduces Bcl-2expression through NF-κBp65:a possible mechanism of hepatocellular carcinoma[J].Asian Pacific Journal of Tropical Medicine,2011,4(6):492-497.
[6]蔡靓羽,张建楠,尹卫娟,等.m TOR抑制剂对大鼠肝癌生长抑制作用的研究[J].中国现代医学杂志,2017,27(2):36-41.
[7]张映林,周世骥,李生伟.VEGF和Notch通路在肝癌血管形成中的作用[J].生理科学进展,2014,45(3):205-208.
[8]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].European Journal of Cancer,2009,45(2):228-274.
[9]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社出版,2002:210-212.
[10]杨宝明,王顺祥,吴晓慧,等.HIF-1α反义寡核苷酸对肝癌细胞增殖凋亡的影响及机制[J].河北医药,2016,38(5):645-649.
[11]Csiki I,Yanagisawa K,Haruki N,et al.Thioredoxin-1modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-lαin non-small cell lung cancer[J].Cancer Res,2006,66(1):143-150.
[12]刘小微,王松坡.缺氧诱导因子对肿瘤多药耐药的影响及其靶向治疗的研究进展[J].现代中西医结合杂志,2015,24(14):1590-1593.
[13]杨昌俊,陈早庆,刘文姣.膀胱癌组织中MCP-1、VEGF、CUGBP1表达相关性及其与癌细胞生长的关系[J].海南医学院学报,2017,23(10):1402-1405.
[14]曲艳红,杨家梅,樊青霞,等.ANXA2、VEGF对Hep G2肝癌细胞系转移的促进作用[J].世界华人消化杂志,2011,19(11):1174-1178.
[15]李国元,赵久达,王成,等.HIF-1α和VEGF在胃癌中的表达及临床意义[J].中国癌症杂志,2010,20(8):602-606.
[16]Kim SE,Shim KN,Jung SA,et al.The clinicophathological significance of tissue levels of hypoxia-inducible factor-1αand vascular endothelial growth factor in gastric cancer[J].Gut and Liver,2009,3(2):88-94.
[2]Lai HC,Lin CC,Cheng KS,et al.Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess:a population-based cohort study[J].Gastroenterology,2014,146(1):129-137.
[3]孟亚平.索拉非尼联合TACE治疗进展期原发性肝癌的临床研究[J].肝脏,2016,21(10):867-870.
[4]Guo Rp,Zhong C,Shim,et al.Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocelluar carcinoma[J].cancer Res clin oncol,2006,132(9):547-555.
[5]Zhao X,Ning Q,Sun X,et al.Pokemon reduces Bcl-2expression through NF-κBp65:a possible mechanism of hepatocellular carcinoma[J].Asian Pacific Journal of Tropical Medicine,2011,4(6):492-497.
[6]蔡靓羽,张建楠,尹卫娟,等.m TOR抑制剂对大鼠肝癌生长抑制作用的研究[J].中国现代医学杂志,2017,27(2):36-41.
[7]张映林,周世骥,李生伟.VEGF和Notch通路在肝癌血管形成中的作用[J].生理科学进展,2014,45(3):205-208.
[8]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].European Journal of Cancer,2009,45(2):228-274.
[9]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社出版,2002:210-212.
[10]杨宝明,王顺祥,吴晓慧,等.HIF-1α反义寡核苷酸对肝癌细胞增殖凋亡的影响及机制[J].河北医药,2016,38(5):645-649.
[11]Csiki I,Yanagisawa K,Haruki N,et al.Thioredoxin-1modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-lαin non-small cell lung cancer[J].Cancer Res,2006,66(1):143-150.
[12]刘小微,王松坡.缺氧诱导因子对肿瘤多药耐药的影响及其靶向治疗的研究进展[J].现代中西医结合杂志,2015,24(14):1590-1593.
[13]杨昌俊,陈早庆,刘文姣.膀胱癌组织中MCP-1、VEGF、CUGBP1表达相关性及其与癌细胞生长的关系[J].海南医学院学报,2017,23(10):1402-1405.
[14]曲艳红,杨家梅,樊青霞,等.ANXA2、VEGF对Hep G2肝癌细胞系转移的促进作用[J].世界华人消化杂志,2011,19(11):1174-1178.
[15]李国元,赵久达,王成,等.HIF-1α和VEGF在胃癌中的表达及临床意义[J].中国癌症杂志,2010,20(8):602-606.
[16]Kim SE,Shim KN,Jung SA,et al.The clinicophathological significance of tissue levels of hypoxia-inducible factor-1αand vascular endothelial growth factor in gastric cancer[J].Gut and Liver,2009,3(2):88-94.